Bionx Implants CEO Gerard Carlozzi Talks to The Wall Street Transcript.Business Editors NEW YORK--(BUSINESS WIRE)--July 17, 2000 The Wall Street Transcript has published an in-depth interview with Gerard Carlozzi, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bionx Implants (Nasdaq:BINX), in which he talks at length about the company's future. The entire 1,900-word interview is available free online at http://www.twst.com/ceos.htm Carlozzi gives an overview of his company, "The company is the leading provider of biomaterial biomaterial /bio·ma·te·ri·al/ (bi?o-mah-ter´e-al) a synthetic dressing with selective barrier properties, used in the treatment of burns; it consists of a liquid solvent (polyethylene glycol-400) and a powdered polymer. solutions using polymer based implant technologies for surgical applications. We are the leader in developing surgical solutions for sports medicine sports medicine, branch of medicine concerned with physical fitness and with the treatment and prevention of injuries and other disorders related to sports. Knee, leg, back, and shoulder injuries; stiffness and pain in joints; tendinitis; "tennis elbow"; and , orthopedic trauma, craniofacial craniofacial /cra·nio·fa·cial/ (kra?ne-o-fa´sh'l) pertaining to the cranium and the face. cra·ni·o·fa·cial adj. Of or involving both the cranium and the face. and urology urology Medical specialty dealing with the urinary system and male reproductive organs. It traces its origin to medieval lithologists, itinerant healers who specialized in surgical removal of bladder stones. using our proprietary technologies. The primary benefit of Bionx products is that they are strong, biologically safe surgical implants that maintain their strength during normal biological healing, and then are resorbed by the body, eliminating the need to remove the device after they have performed their function." Carlozzi explains, "When the Meniscus meniscus /me·nis·cus/ (me-nis´kus) pl. menis´ci [L.] something of crescent shape, as the concave or convex surface of a column of liquid in a pipet or buret, or a crescent-shaped cartilage in the knee joint. Arrow was introduced, the company's sales more than doubled in a very short period of time. The company very quickly became labeled as the Meniscus Arrow Company. Bionx has been able to maintain a greater than 60% market share for meniscus repair devices. We have been redirecting the focus of the company during the past year to expand our product portfolio and market penetration Noun 1. market penetration - the extent to which a product is recognized and bought by customers in a particular market penetration - the act of entering into or through something; "the penetration of upper management by women" in the orthopedic sports medicine, orthopedic trauma, spine, urology, cardiovascular, and other markets via direct marketing and corporate partnerships." Looking forward, Carlozzi states, "The company has refocused its efforts and has continued to invest in new areas to expand the application of the company's technology. To minimize the risk of sales based on the success of a single product, we are strengthening our critical resources and expanding our product portfolio to have a wider range of products from which we generate our revenues." This interview is part of a 110-page Drug & Medical Supply Distributors Issue available at http://www.twst.com/info/info132.htm or by calling (212) 952-7433 The Wall Street Transcript is a premier weekly investment publication serving serious long-term investors Long-term investor A person who makes investments for a period of at least five years in order to finance his or her long-term goals. for over 37 years. The Wall Street Transcript has launched a new free service where investors can ask Bionx Implants (or any public company) a question at http://www.qawire.com The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call (800) 246-7673. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion